Search for the latest oncology news by tumour type
AACR 2024: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favourable safety profile in…